574 related articles for article (PubMed ID: 15702813)
1. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
2. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
[TBL] [Abstract][Full Text] [Related]
3. [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)].
Boehncke S; Boehncke WH
Dtsch Med Wochenschr; 2005 Oct; 130(40):2249-52. PubMed ID: 16208597
[TBL] [Abstract][Full Text] [Related]
4. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
6. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
Bavbek S; Celik G; Ediger D; Mungan D; Demirel YS; Misirligil Z
J Asthma; 1999 Dec; 36(8):657-63. PubMed ID: 10609620
[TBL] [Abstract][Full Text] [Related]
7. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.
Asero R
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):554-8. PubMed ID: 10400483
[TBL] [Abstract][Full Text] [Related]
9. [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].
Ahlbach S; Usadel KH; Kaufmann R; Boehncke WH
Med Klin (Munich); 2003 Apr; 98(5):242-4. PubMed ID: 12721666
[TBL] [Abstract][Full Text] [Related]
10. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
[TBL] [Abstract][Full Text] [Related]
11. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema.
Colanardi MC; Nettis E; Traetta P; Daprile C; Fitto C; Aloia AM; Di Leo E; Ferrannini A; Vacca A
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):82-5. PubMed ID: 18254487
[TBL] [Abstract][Full Text] [Related]
12. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
13. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
14. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Stevenson DD; Simon RA
J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
[TBL] [Abstract][Full Text] [Related]
15. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Kelkar PS; Butterfield JH; Teaford HG
J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
[TBL] [Abstract][Full Text] [Related]
16. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
[TBL] [Abstract][Full Text] [Related]
17. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
18. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children.
Kidon MI; Kang LW; Chin CW; Hoon LS; See Y; Goh A; Lin JT; Chay OM
Pediatrics; 2005 Nov; 116(5):e675-80. PubMed ID: 16230465
[TBL] [Abstract][Full Text] [Related]
19. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
